In recent years outlays on the Australian Pharmaceutical Benefits Scheme have increased rapidly, prompting both attempts by government to reduce growth in outlays and renewed interest in the characteristics of the beneficiaries of the Scheme. This article uses a microsimulation model to analyse...

Finding ways of curbing government expenditure on the Pharmaceutical Benefits Scheme (PBS) while maintaining social equity and access to 'essential' medicines is at the centre of ongoing public debate. This article describes a microsimulation model of the PBS that simulates current and future...